World Sleep Industry ENCYCLOPEDIA

Multi-Center Clinical Trial Operations

6.5.1

Definition, service scope, and protocol-design boundary

Multi-center clinical trial operations coordinate activation, enrollment, intervention delivery, assessment, data, safety, quality, supply, and closeout at two or more research sites under an approved protocol, statistical analysis plan, monitoring plan, and safety plan. The service belongs to WSIC 6.5.1, Clinical Trial Services. Sleep trials may study drugs, devices, digital therapeutics, behavioral interventions, or service models and may use PSG, HSAT, actigraphy, wearables, physiological sensors, questionnaires, and remote visits. Operational quality means that participant protection and critical data processes follow the same controlled version across institutions, personnel, equipment, languages, time zones, and care settings, and that site-to-site differences become visible in time. It is not simply the number of activated sites or the speed of enrollment.

This service is distinct from protocol design, statistical analysis, participant recruitment, central laboratories, sleep interpretation, data management, pharmacovigilance, and regulatory submission. One provider may perform several of these functions, but scope, qualifications, and accountability require separate definition. Operations teams can provide feasibility feedback and propose amendments; they cannot change the research question, endpoints, eligibility, randomization, intervention, or safety rules without the required approval. A sponsor may transfer tasks to a CRO, coordinating center, or vendor but still retains appropriate oversight. An investigator's responsibility for care and conduct at a site, and the functions of ethics committees and regulators, do not disappear through outsourcing.

Governance, responsibility matrices, and quality planning

Before activation, the sponsor, coordinating investigator, site principal investigators, CRO, project management, medical monitoring, data management, statistics, pharmacovigilance, central reading, laboratory, technology and logistics vendors, ethics review, and independent data monitoring bodies need a responsibility matrix. It should identify decision rights, approvals, on-call contacts, time-zone coverage, information barriers, blinding protections, escalation of serious issues, backups, and oversight of subcontractors. A committee name is not a charter. Steering, data and safety monitoring, endpoint adjudication, and quality groups should define qualifications, independence, meeting materials, conflicts, quorum, recipients of recommendations, and records.

The quality plan should focus on factors critical to participant rights and safety and the reliability of results. For each vulnerable process, it should identify causes, consequences, prevention, detection, thresholds, and an owner. Risks may include consent errors, ineligible enrollment, late safety reporting, randomization or blind compromise, lost sleep signals, device or firmware differences, scoring drift, interrupted intervention supply, inconsistent definitions, and loss of key staff. Monitoring frequency and control intensity can change with risk, complexity, and accumulated evidence, but risk proportionality does not mean omission of necessary oversight. Quality tolerance boundaries, trigger signals, and treatment of important deviations should be defined in advance and reviewed as evidence changes.

Site feasibility, activation, and version readiness

Site selection should use verifiable evidence for the target population, previous recruitment and retention, competing studies, referral routes, investigator availability, overnight staff, beds and sleep equipment, emergency capability, laboratories and imaging, product storage, network and transfer capacity, language, accessibility, contracts, and local review timelines. Crude electronic health record counts and self-reported pools commonly overstate eligible participants. Estimates should account for diagnosis, eligibility, distance, overnight burden, digital access, and willingness. Selection should not reward only optimistic recruitment speed; representation, quality history, actual resources, and the ability to support participants also matter.

Before the first participant activity at a site, applicable regulatory and ethics approvals, reliance or authorization agreements, contracts and budgets, insurance or indemnity, privacy and data arrangements, laboratory and equipment qualification, supplies, delegation, training, and system access must be ready. A central ethics review or single IRB can reduce duplicated review but still requires written allocation between the reviewing body and relying sites and communication of local culture, language, institutional capacity, and law. The activation package should contain only approved versions of the protocol, consent, manuals, scales, randomization, and safety material. Amendments need tracked approval, training, effective dates, withdrawal of obsolete copies, and assessment of already enrolled participants; sites cannot choose their preferred version.

Recruitment, consent, participant journeys, and decentralized elements

Recruitment plans should track contact, prescreening, consent, screen failure, randomization, retention, and withdrawal reasons by site and population and verify approval of advertising, referrals, social media, and third parties. Targets and incentives must not encourage relaxed eligibility, hidden risks, repeated contact after refusal, or shortened decision time. Consent uses understandable language, accommodates translation, literacy, hearing, vision, or cognition, provides a qualified person to answer questions, and preserves the current approved form. Burdens such as overnight PSG, withdrawal of existing treatment, home devices, transportation, caregivers, shift work, and next-day driving risk should appear honestly in scheduling and support.

Remote visits, electronic consent, home nursing, local providers, direct-to-participant delivery, and digital health technologies may reduce travel but do not reduce protection or data expectations. Operations must define which activities can occur remotely, how identity, location, and authority are checked, who handles technical failures, abnormal signals, emergencies, device returns, and privacy complaints, and what fallback applies when remote capture fails. Bring-your-own devices, lost connectivity, reminders across time zones, answers entered by household members, and changes in the home setting can create systematic bias. These conditions need recording and consistent handling across sites instead of an assumption that a remote measurement is automatically equivalent to an on-site one.

Sleep measurement, intervention supply, and cross-site consistency

The sleep measurement manual should control device and firmware, channels or sensors, sampling, units, filters, clock synchronization, calibration, placement, lights-off and lights-on markers, valid-record criteria, failed-test repeats, file formats, and transfer paths. PSG and HSAT scoring system, version, epoch, and event rules; actigraphy wear and non-wear handling; questionnaire and diary windows; and wearable or digital metric algorithms need harmonization. Central reading can reduce site variability, but upload completeness, blinding, reader qualification, inter-scorer reliability, review and adjudication, and drift still require verification. Automated scoring needs a retained version and human oversight; aggregate agreement must not conceal systematic differences by site, stage, or event class.

Randomization systems, blinded materials, investigational products, devices, consumables, and training accounts require authorized generation, packaging, shipment, receipt, storage, dispensing, return, and reconciliation, including temperature excursions, damage, shortage, expiry, and recall. Medication use, PAP or oral appliances, digital therapeutics, light or sound environments, and behavioral interventions should receive consistent training and adherence recording without changing intervention content to improve apparent adherence. Emergency unblinding follows predefined authority and medical need and records the person, time, reason, and effect. Sham or control interventions also require assessment of detectability, user burden, and site-level delivery differences.

Data flows, risk-based monitoring, and safety closure

A data-flow map should cover source records, electronic data capture, electronic health records, laboratories, randomization, ePRO, DHTs, central reading, imaging or signal repositories, and safety databases. It defines provenance, identifier mapping, interfaces, time zones, units, edit checks, queries, lock, and archival. Electronic systems need fit-for-purpose validation, unique accounts, least privilege, traceable changes, reviewable audit trails, and downtime and retransmission plans. Risk-based monitoring may combine central statistics, remote document review, and on-site work and prioritize consent, eligibility, primary endpoints, safety, blinding, and unusual site patterns. It is not the elimination of source verification, and large volumes of low-risk queries cannot compensate for loss of control over a critical process.

Adverse events, serious events, events of special interest, pregnancy, and device deficiencies require identification, medical assessment, follow-up, deduplication, escalation, and reporting under the protocol and applicable requirements, with clear paths and timelines among sites, medical monitors, sponsors, safety committees, and ethics bodies. Sleep trials may also encounter material hypoxemia, cardiac or behavioral findings, next-day alertness and driving risks, falls, skin injury from devices, home hazards, and intervention-related worsening; the approved protocol and medical plan, not a generic service rule, define specific triggers. Safety signals, deviations, data anomalies, complaints, and privacy incidents should enter one issue process recording containment, cause, corrective and preventive action, affected scope, and closure evidence.

Closeout, disclosure, performance interpretation, and claim boundaries

Site closeout should confirm participant follow-up or referral, unresolved safety matters, product and specimen reconciliation, query resolution, signatures, essential records, revoked access, returned equipment, vendor data transfer, and compliant archiving. Early closure of a site or the whole trial also requires reasons and participant protections. Operations should maintain registration information, site status, and recruitment and completion dates and support the responsible party in submitting results, protocols, and statistical material where required. Negative, null, or early-terminated results should not vanish because they are commercially inconvenient. Major deviations, missingness, and blinding issues require resolution before database lock; post-lock changes must be controlled rather than silently made to meet a report date.

Metrics may include activation cycle time, forecast versus actual enrollment, representation, screen failure, retention, timeliness of critical assessments, usable-signal rate, query aging, deviations, safety reporting, monitoring findings, remediation, and data completeness, interpreted with denominators, risk, and site context. Simple rankings can drive inappropriate recruitment or under-reporting, and a site that detects and reports problems should not automatically be labeled poor quality. Good operations cannot guarantee recruitment, absence of bias or events, regulatory acceptance, product authorization, or clinical efficacy, and one jurisdiction's template is not global compliance. A mature service is judged by clear accountability, consistent versions, visible issues, verifiable evidence, and participant protection, not claims of turnkey operation, freedom from regulatory risk, or guaranteed approval.